Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition

American Journal of Hematology

Volumn 85, Issue 8, 2010, Pages 616-619

  Barosi, Giovanni ^a   Gattoni, Elisabetta ^a   Guglielmelli, Paola ^b   Campanelli, Rita ^a   Facchetti, Fabio ^c   Fisogni, Simona ^c   Goldberg, Judith ^d   Marchioli, Roberto ^e   Hoffman, Ronald ^f   Vannucchi, Alessandro M ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Consorzio Mario Negri Sud ^*  (Italy)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD34 ANTIBODY; CHEMOKINE RECEPTOR CXCR4; PROTEASOME INHIBITOR; ANGIOGENESIS INHIBITOR; BORONIC ACID DERIVATIVE; PROTEASOME; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; BIOLOGICAL ACTIVITY; BONE MARROW; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MONONUCLEAR CELL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; REPEATED DRUG DOSE; THROMBOCYTOPENIA; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; INTRAVENOUS DRUG ADMINISTRATION; LETTER; MIDDLE AGED; MYELOID METAPLASIA; PATHOLOGY; RISK; SALVAGE THERAPY; TREATMENT FAILURE; VASCULARIZATION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; BONE MARROW; BORONIC ACIDS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RISK; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT FAILURE; YOUNG ADULT;

EID: 77955505961     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21754     Document Type: Article

References (28)

1. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895-2901.
2. Komura E, Tonetti C, Penard-Lacronique V, et al. Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression. Cancer Res 2005;65:3281-3289.
3. Rameshwar P, Narayanan R, Qian J, et al. NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunol 2000;165:2271-2277.
4. Ni H, Barosi G, Hoffman R. Quantitative evaluation of bone marrow angiogenesis in idiopathic myelofibrosis. Am J Clin Pathol 2006;126:241-247.
5. Barosi G, Rosti V, Massa M, et al. Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2004;24:618-625.
6. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108:1497-1503.
7. Mesa RA, Verstiovsek S, Rivera C, et al. Bortezomib therapy in myelofibrosis: A phase II clinical trial. Leukemia 2008;22:1636-1638.
8. Palumbo A, Magarotto V, Gay F, et al. Update on recent developments for patients with newly diagnosed multiple myeloma. Ann N Y Acad Sci. 2008; 1138:19-21.
9. Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20:520-525.
10. Kastritis E, Anagnostopoulos A, Roussou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007;92:1351-1358.
11. Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:4293-4297.
12. Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Results of WMCTG Trial 03-248. Clin Cancer Res 2007;13:3320-3325.
13. Troch M, Jonak C, Müllauer L, et al. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica 2009;94:738-742.
14. Drexler HC, Risau W, Konerding MA. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 2000; 14:65-77.
15. Nawrocki ST, Bruns CJ, Harbison MT, et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2002;1:1243-1253.
16. Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7: 1419-1428.
17. Hamner JB, Dickson PV, Sims TL, et al. Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma. Surgery 2007;142:185-191.
18. Politou M, Naresh K, Terpos E, et al. Anti-angiogenic effect of bortezomib in patients with multiple myeloma. Acta Haematol 2005;114:170-173.
19. Cibeira MT, Rozman M, Segarra M, et al. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. Cytokine 2008;41:244-253.
20. Duechler M, Shehata M, Schwarzmeier JD, et al. Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2. Leukemia 2005;19:260-267.
21. Noborio-Hatano K, Kikuchi J, Takatoku M, et al. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene 2009;28:231-242.
22. Wang X, Ottosson A, Ji C, et al. Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity. Haematologica 2009;94:470-478.
23. Blanco B, Perez-Simon JA, Sanchez-Abarca LI, et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006;107:3575-3583.
24. Thiele J, Kvasnicka HM, Facchetti F, et al. EUMNET European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90:1128-1132.
25. Keeney M, Chin-Yee I, Weir K, et al. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. Cytometry 1998;34:61-70.
26. Cilloni D, Messa F, Arruga F, et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica 2008;93: 921-924.
27. Rosti V, Massa M, Vannucchi AM, et al. The expression of CXCR4 is downregulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis 2007;38:280-286.
28. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007;21:1952-1959.